Using dynamic treatment regimes to understand erythropoietin-stimulating agent hyporesponsiveness
Sign Up to like & getrecommendations! Published in 2018 at "Pediatric Nephrology"
DOI: 10.1007/s00467-018-3948-9
Abstract: BackgroundErythropoietin-stimulating agent hyporesponsiveness (ESAH) is associated with increased cardiovascular mortality in patients with end-stage renal disease (ESRD) on hemodialysis. Dynamic treatment regimes (DTR), a clinical decision support (CDS) tool that guides the prescription of specific… read more here.
Keywords: treatment regimes; dynamic treatment; treatment; stimulating agent ... See more keywords
Addition of roxadustat to erythropoiesis‐stimulating agent (ESA) effectively corrects ESA‐hyporesponsive anaemia in patients on peritoneal dialysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13696
Abstract: Erythropoiesis‐stimulating agent (ESA) hyporesponsiveness is an important cause for the undertreatment of anaemia. A decrease in haemoglobin (Hb) levels was observed during the initial stage of the conversion from ESA to roxadustat. The study aims… read more here.
Keywords: erythropoiesis stimulating; hyporesponsive anaemia; agent esa; stimulating agent ... See more keywords